New Stock News | Baili Kang submitted documents to the Hong Kong Stock Exchange, the company's core products include three ADCs in clinical stages, namely BB-1701, BB-1705, etc.

According to the disclosure on June 29 by the Hong Kong Stock Exchange, BlissBio Inc. (referred to as BlissBio) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Goldman Sachs, Huatai International, and J.P. Morgan as joint sponsors. According to the prospectus, BlissBio is a clinical-stage biopharmaceutical company dedicated to developing the next generation of antibody-drug conjugates (ADCs) to address important unmet needs in cancer treatment. Strategically, the company has designed and advanced an ADC pipeline consisting of four clinical-stage candidate drugs. The core product, BB-1701, is a human epidermal growth factor receptor 2 (HER2) targeted Adcetris ADC candidate drug, primarily targeting breast cancer (BC), non-small cell lung cancer (NSCLC), and other potential HER2-expressing cancers. In addition to the core product, the company also has three other clinical-stage ADCs: BB-1705 (an epidermal growth factor receptor (EGFR) ADC), BB-1712 (a B7 homolog 3 (B7-H3) ADC), and BB-1709 (a differentiation cluster 73 (CD73) ADC), which have potential in a wide range of indications. All of the company's pipeline assets have full global rights. BB-1701 is the leading global clinical-stage HER2 ADC candidate drug designed for or used in TOP1-i ADC-treated patients. Utilizing Adcetris as the ADC payload, BB-1701 takes advantage of Adcetris's multifaceted mechanism of action, differentiated resistance mechanisms, and clinical-validated efficacy and safety in cancer treatment approved in over 70 countries worldwide. Based on phase 2 studies currently conducted in the United States, Europe, Japan, and China, BB-1701 has shown promising efficacy and manageable safety, with only three cases of ILD (two grade 1, one grade 2) out of 260 patients, showing improvement over Adcetris. The company's internal chemistry, manufacturing, and control (CMC) development and manufacturing capabilities provide essential solutions for high-quality, efficient, and cost-effective antibody development, conjugation processes, formulation, and ADC construction. By following the principle of "process as product," robust production processes are established, ensuring strict quality control and assurance throughout the development cycle. These capabilities have enabled the company to advance projects from preclinical candidates to investigational new drug (IND) status in new drug clinical trials within 14 months, which is significantly faster than the industry average of 18 months, according to Frost & Sullivan data. Multiple IND approvals granted by global regulatory agencies such as the United States, China, the European Union, and Japan attest to the company's CMC platform capabilities. In terms of finance, BlissBio achieved revenues of approximately 180 million yuan and 225.91 million yuan in the fiscal years 2023 and 2024, respectively, with losses of approximately 206 million yuan and 557 million yuan in the same period.